Critical Pharmacodynamic Warning
escitalopram affects the 2C19 metabolic pathway.
When patients take escitalopram concurrently with drugs metabolized by 2C19, the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.
Clinical Impact: As a strong inhibitor , escitalopram can alter the metabolism of substrate drugs, requiring careful monitoring and potential dose adjustments.
Clinical Overview for escitalopram
This page outlines known interaction pathways involving escitalopram, focusing primarily on its profile as a Strong inhibitor affecting the 2C19 pathway.
Enzyme Interaction Profile
escitalopram demonstrates strong inhibitor potency against 2C19. Clinical significance of this interaction requires further evaluation.
Inhibitor
A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.
Clinical Example: escitalopram affects 2C19Inducer
A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.
Interaction Details
| Drug Name | escitalopram |
| Affected Enzyme | 2C19 |
| Inhibitor Strength | Strong inhibitor Unknown |
| Inducers | No inducers listed |
| Inhibitors | fluvoxamine |
Clinical Recommendations
Consult primary literature for guidance.
- Therapeutic drug levels
- Adverse effect monitoring
- Clinical response assessment
- Consider dose reduction
- Evaluate alternative therapies
- Adjust based on response
Quick Facts
5032
2C19
Enzyme Inhibition
Unknown
Clinical Significance
Clinical significance requires further evaluation.
Information Sources
- FDA Drug Interaction Database
- Clinical Pharmacology Guidelines
- Pharmaceutical Labeling Information
- Published Clinical Studies
Last updated: June 12, 2026